UnitedHealthcare Community Plan

NC Pharmacy Prior Approval Request for

Evrysdi

Beneficiary Information

1. Beneficiary Last Name: _____ 2. First Name: _____
3. Beneficiary ID #: _____ 4. Beneficiary Date of Birth: _____ 5. Beneficiary Gender: _____

Prescriber Information

6. Prescribing Provider NPI #: _____
7. Requester Contact Information - Name: _____ Phone #: _____ Ext._____

Drug Information

8. Drug Name:_____ 9. Strength: _____ 10. Quantity Per 30 Days:_____
11. Length of Therapy (in days): ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days ☐ 365 Days ☐ Other _____

Clinical Information

For initial authorization requests, please answer questions 1-6

1. Is the patient 2 years of age or older? ☐ **Yes** ☐ **No**
2. Does the beneficiary have a diagnosis of 5q-autosomal recessive spinal muscular atrophy (SMA)? ☐ **Yes** ☐ **No**
3. Does the beneficiary have SMA phenotype 1, 2, 3? ☐ **Yes** ☐ **No**
4. Will the beneficiary use Evrysdi concomitantly with nusinersen (Spinraza) or onasemnogene abeparvovec-xioi (Zolgensma)? ☐ **Yes** ☐ **No**
5. Is this medication being prescribed by or in consultation with a neurologist? ☐ **Yes** ☐ **No**
6. Does the beneficiary require invasive ventilation or tracheostomy? ☐ **Yes** ☐ **No**

For reauthorization, please answer questions 1-5 and 7-9

7. Does the Beneficiary continue to meet the above criteria? ☐ **Yes** ☐ **No**
8. Has the beneficiary experience any treatment related adverse effects or unacceptable toxicity?
9. Has the beneficiary had clinically meaningful response to treatment as demonstrated by at least 1 of the following:
   - ☐ Stability or improvement in net motor function/milestones, including but not limited to the following validated scales: Hammersmith Infant Neurologic Exam (HINE), Hammersmith Functional Motor Scale Expanded (HFMSE), Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), Bayley Scales of Infant and Toddler development Third Ed. (BSID-III), 6-minute walk test (6MWT), upper limb module (ULM), etc.
   - ☐ Stability or improvement in respiratory function tests [e.g. forced vital capacity (FVC), etc.]
   - ☐ Reduction in exacerbations necessitating hospitalization and/or antibiotic therapy for respiratory infection in the preceding year/timeframe
   - ☐ Stable or increased patient weight (for patients without a gastrostomy tube)
   - ☐ Slowed rate of decline in the aforementioned measures

Signature of Prescriber: _____ Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to 1-866-940-7328 Pharmacy PA Call Center: 1-855-258-1593